Advanced strategies for extending the blood circulation time of nano-based delivery systems
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Clinical cancer nanomedicines10.1016/j.jconrel.2025.113991 ↗
2. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
3. Why nanoparticles prefer liver macrophage cell uptake in vivo10.1016/j.addr.2022.114238 ↗
4. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
5. Long-circulating and target-specific nanoparticles: theory to practice10.1016/S0031-6997(24)01494-7 ↗
6. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects10.2174/138161210791920496 ↗
7. Beyond PEGylation: nanoparticle surface modulation for enhanced cancer therapy10.1186/s44301-025-00014-4 ↗
8. W. Bao, F. Tian, C. Lyu, B. Liu, B. Li, L. Zhang, X. Liu, F. Li, D. Li, X. Gao, S. Wang, W. Wei, X. Shi, Y. Li, Experimental and theoretical explorations of nanocarriers’ multistep delivery performance for rational design and anticancer prediction, Science Advances 7 (n.d.) eaba2458. https://doi.org/10.1126/sciadv.aba2458.10.1126/sciadv.aba2458 ↗
9. The ancillary effects of nanoparticles and their implications for nanomedicine10.1038/s41565-021-01017-9 ↗
10. Personalized protein corona on nanoparticles and its clinical implications10.1039/C6BM00921B ↗
11. Precision nanomedicine development based on specific opsonization of human cancer patient-personalized protein coronas10.1021/acs.nanolett.9b01774 ↗
12. Nanoparticle uptake: the phagocyte problem10.1016/j.nantod.2015.06.006 ↗
13. Nanoparticle elasticity affects systemic circulation lifetime by modulating adsorption of apolipoprotein AI in corona formation10.1038/s41467-022-31882-4 ↗
14. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles10.1038/s41565-018-0344-3 ↗
15. Engineering long-circulating nanomaterial delivery systems10.1016/j.copbio.2020.07.006 ↗
16. A brief history of long circulating nanoparticles10.1016/j.addr.2022.114396 ↗
17. Irina MuljajewStealth Effect of Short Polyoxazolines in Graft Copolymers: Minor Changes of Backbone End Group Determine Liver Cell-Type Specificity, (n.d.).
18. Metabolism of nanomaterials in vivo: blood circulation and organ clearance10.1021/ar2003336 ↗
19. Tissue-specific macrophages: how they develop and choreograph tissue biology10.1038/s41577-023-00848-y ↗
20. Bioinert, stealth or interactive: how surface chemistry of nanocarriers determines their fate in vivo10.1002/adfm.202103347 ↗
21. Stealth nanoparticles in oncology: Facing the PEG dilemma10.1016/j.jconrel.2022.09.002 ↗
22. Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy10.1016/j.biomaterials.2022.121415 ↗
23. Inherent anti-HIV activity of biocompatible anionic citrate-PEG-citrate dendrimer10.1007/s11033-018-4455-6 ↗
24. Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice10.1080/21691401.2017.1290642 ↗
25. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives10.1016/j.addr.2021.114079 ↗
26. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes10.1016/0014-5793(90)81016-H ↗
27. Polymeric micelles with α-glutamyl-terminated PEG shells show low non-specific protein adsorption and a prolonged in vivo circulation time10.1016/j.msec.2015.10.084 ↗
28. Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol)10.1038/s41467-020-19947-8 ↗
29. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics10.1038/s41467-017-00600-w ↗
30. Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation10.1021/acsnano.8b04947 ↗
31. Bing-Mae Chen 2021, Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies, (n.d.).10.1021/acsnano.1c05922 ↗
32. Alternating stealth polymer coatings between administrations minimizes toxic and antibody immune responses towards nanomedicine treatment regimens10.1016/j.actbio.2020.11.047 ↗
33. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes10.1016/j.biomaterials.2010.02.049 ↗
34. Collagenase IV and clusterin-modified polycaprolactone-polyethylene glycol nanoparticles for penetrating dense tumor tissues10.7150/thno.47446 ↗
35. Sensing surface PEGylation with microcantilevers10.3762/bjnano.1.2 ↗
36. Brush conformation of polyethylene glycol determines the stealth effect of nanocarriers in the low protein adsorption regime10.1021/acs.nanolett.0c03756 ↗
37. Surface hydration: principles and applications toward low-fouling/nonfouling biomaterials10.1016/j.polymer.2010.08.022 ↗
38. Beyond Poly(ethylene glycol): linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications10.1021/bm5002608 ↗
39. Self-assembled monothiol-terminated hyperbranched polyglycerols on a gold surface: a comparative study on the structure, morphology, and protein adsorption characteristics with linear poly(ethylene glycol)s10.1021/la702867t ↗
40. Blood circulation of soft nanomaterials is governed by dynamic remodeling of protein opsonins at nano-biointerface10.1038/s41467-020-16772-x ↗
41. The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles10.1016/j.biomaterials.2014.04.038 ↗
42. Polyglycerol and Poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces10.1016/j.biomaterials.2022.121676 ↗
43. Poly(2-ethyl-2-oxazoline) (POx) as Poly(ethylene glycol) (PEG)-Lipid Substitute for Lipid Nanoparticle Formulations10.1002/smll.202411354 ↗
44. Poly(2-ethyl-2-oxazoline) as Alternative for the Stealth Polymer Poly(ethylene glycol): Comparison of in vitro Cytotoxicity and Hemocompatibility10.1002/mabi.201200017 ↗
45. Tuning the surface of nanoparticles: impact of poly(2-ethyl-2-oxazoline) on protein adsorption in serum and cellular uptake10.1002/mabi.201600074 ↗
46. Human plasma proteome association and cytotoxicity of nano-graphene oxide grafted with stealth polyethylene glycol and poly(2-ethyl-2-oxazoline)10.1039/C8NR00835C ↗
47. Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s10.1016/j.jconrel.2007.02.015 ↗
48. Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications10.1016/j.eurpolymj.2016.09.052 ↗
49. PEGylation technology: addressing concerns, moving forward10.1080/10717544.2025.2494775 ↗
50. Novel zwitterionic vectors: Multi-functional delivery systems for therapeutic genes and drugs10.1016/j.csbj.2020.07.015 ↗
51. Rational design of cancer nanomedicine for simultaneous stealth surface and enhanced cellular uptake
52. Size-dependent EPR effect of polymeric nanoparticles on tumor targeting10.1002/adhm.201901223 ↗
53. Progress in biodegradable zwitterionic materials10.1016/j.polymdegradstab.2017.03.015 ↗
54. Doxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy10.1039/C4TB01984A ↗
55. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior10.1016/j.biomaterials.2014.11.010 ↗
56. Hydrolytically Degradable Zwitterionic Polyphosphazene Containing HEPES Moieties as Side Groups10.1021/acs.biomac.4c01008 ↗
57. Blood retention and antigenicity of polycarboxybetaine-modified liposomes10.1016/j.ijpharm.2020.119521 ↗
58. Superhydrophilic zwitterionic polymers stabilize liposomes10.1021/la302433a ↗
59. Polycarboxybetaine in advanced drug delivery systems: From structure-function relationship to therapeutic applications
60. Zwitterionic stealth peptide-protected gold nanoparticles enable long circulation without the accelerated blood clearance phenomenon10.1039/C7BM00747G ↗
61. The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine10.1016/j.addr.2021.04.028 ↗
62. Design of smart size-, surface-, and shape-switching nanoparticles to improve therapeutic efficacy
63. When imaging meets size-transformable nanosystems10.1016/j.addr.2022.114176 ↗
64. Hypoxia-Targeting, Tumor Microenvironment Responsive Nanocluster Bomb for Radical-Enhanced Radiotherapy10.1021/acsnano.7b04737 ↗
65. A near-infrared light-responsive extracellular vesicle as a “Trojan horse” for tumor deep penetration and imaging-guided therapy10.1016/j.biomaterials.2020.120647 ↗
66. Nanoparticles with transformable physicochemical properties for overcoming biological barriers10.1039/D3NR01332D ↗
67. Dual pH/redox-responsive hyperbranched polymeric nanocarriers with TME-trigger size shrinkage and charge reversible ability for amplified chemotherapy of breast cancer10.1038/s41598-024-57296-4 ↗
68. Tumor Microenvironment-Responsive Nanoshuttles with Sodium Citrate Modification for Hierarchical Targeting and Improved Tumor Theranostics10.1021/acsami.9b07957 ↗
69. Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy10.1038/s41565-019-0485-z ↗
70. Shape switching of CaCO3-templated nanorods into stiffness-adjustable nanocapsules to promote efficient drug delivery10.1016/j.actbio.2021.04.011 ↗
71. Stiffness-transformable nanoplatforms responsive to the tumor microenvironment for enhanced tumor therapeutic efficacy10.1002/anie.202216361 ↗
72. Switchable PAMAM megamers for deep tumor penetration and enhanced cell uptake10.1016/j.jconrel.2024.09.031 ↗
73. Overcoming the Reticuloendothelial System Barrier to Drug Delivery with a “Don’t-Eat-Us” Strategy10.1021/acsnano.9b05679 ↗
74. Effect of removing Kupffer cells on nanoparticle tumor delivery10.1073/pnas.1713390114 ↗
75. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery10.1038/s41467-024-48838-5 ↗
76. Fucoidan prolongs the circulation time of dextran-coated iron oxide nanoparticles10.1021/acsnano.7b06734 ↗
77. Regulating interactions between targeted nanocarriers and mononuclear phagocyte system via an esomeprazole-based preconditioning strategy10.2147/IJN.S258054 ↗
78. Boosting nanomedicine performance by conditioning macrophages with methyl palmitate nanoparticles10.1039/D1MH00937K ↗
79. Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines10.1126/sciadv.abb8133 ↗
80. Just dose it10.1038/s41563-020-00855-7 ↗
81. The dose threshold for nanoparticle tumour delivery10.1038/s41563-020-0755-z ↗
82. RES blockade: A strategy for boosting efficiency of nanoparticle drug10.1016/j.nantod.2014.12.003 ↗
83. Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes10.1038/s41551-020-0581-2 ↗
84. Toward Understanding in Vivo Sequestration of Nanoparticles at the Molecular Level10.1021/acsnano.8b00141 ↗
85. Extracellular vesicles for the delivery of gene therapy10.1038/s44222-025-00277-7 ↗
86. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium10.7150/thno.38198 ↗
87. Activation of the complement system by nanoparticles and strategies for complement inhibition10.1016/j.ejpb.2023.11.006 ↗
88. Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions10.1016/j.jconrel.2023.02.022 ↗
89. Biomaterial design for proactive modulation of the complement system10.1038/s44222-025-00281-x ↗
90. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins10.1038/s41565-023-01514-z ↗
91. Overcoming Hepatic Biotransformation Barrier of Gold Nanoparticles via Au–Se Bond for Enhanced In Vivo Active Targeting10.1021/acsnano.4c10700 ↗
92. pH/redox responsive size-switchable intelligent nanovehicle for tumor microenvironment targeted DOX release10.1038/s41598-023-49446-x ↗
93. Impact of glutathione modulation on stability and pharmacokinetic profile of redox-sensitive nanogels10.1002/smll.201704093 ↗
94. Controlling the biodistribution and clearance of nanomedicines10.1038/s44222-023-00138-1 ↗
95. Glutathione-mediated biotransformation in the liver modulates nanoparticle transport10.1038/s41565-019-0499-6 ↗
96. Quantitative Analysis of Protein Corona on Precoated Protein Nanoparticles and Determined Nanoparticles with Ultralow Protein Corona and Efficient Targeting in Vivo10.1021/acsami.1c12008 ↗
97. In vivo protein corona on nanoparticles: does the control of all material parameters orient the biological behavior?10.1039/D0NA00863J ↗
98. Phosphatidylcholine-Coated Iron Oxide Nanomicelles for In Vivo Prolonged Circulation Time with an Antibiofouling Protein Corona10.1002/chem.201404221 ↗
99. Photothermal effect of albumin-modified gold nanorods diminished neuroblastoma cancer stem cells dynamic growth by modulating autophagy10.1038/s41598-022-15660-2 ↗
100. The effects of protein corona on in vivo fate of nanocarriers10.1016/j.addr.2022.114356 ↗